Cyrano Therapeutics and Resyca Announce Exclusive License Agreement for Soft Mist Nasal Spray Technology for the Treatment of Chemosensory Dysfunction

Soft Mist Nasal Spray Technology Designed to Enhance Drug Deposition in the Olfactory Region, Increasing the Potential for CYR-064's Therapeutic Efficacy

DELRAY BEACH, Fla and ENSCHEDE, Netherlands, March 18, 2025 /PRNewswire/ -- Cyrano Therapeutics, a clinical-stage regenerative medicine company pioneering the development of treatments for smell loss, and Resyca, a leading innovator in soft mist inhaler and soft nasal spray technologies, today announced they have entered into an exclusive licensing agreement for Resyca's proprietary soft mist nasal spray technology for the treatment of chemosensory disorders, including post-viral smell loss (hyposmia).

This agreement marks a major milestone in advancing an innovative treatment to address this critical unmet medical need. Cyrano Therapeutics' lead therapy, CYR-064, has progressed its Phase 2 FLAVOR clinical study utilizing Resyca's soft mist nasal spray technology, with top-line data expected in the second half of 2025.

Resyca's proprietary soft mist nasal spray technology is designed to optimize drug deposition in the nasal cavity and the olfactory region. Specific to CYR-064,  the precisely controlled droplet size and low spray velocity have the potential to improve drug distribution to the target olfactory region, thereby increasing the opportunity for therapeutic efficacy. Integrated into Ursatec's spray pump technology, Resyca's soft mist technology offers a patient-friendly design that supports safe and effective administration, making it particularly well-suited for treating persistent smell loss.

"This agreement with Resyca enables us to enhance the efficacy of our treatment for patients experiencing chemosensory dysfunction by delivering our proprietary formulation through their advanced soft mist technology," said Rick Geoffrion, CEO of Cyrano Therapeutics. "Resyca's soft mist technology plays a critical role in optimizing the deposition and delivery of CYR-064 in the olfactory region to maximize its therapeutic potential. This advanced delivery system has been integral to our Phase 2 FLAVOR trial, which is currently wrapping up enrollment."

Remko Beimers, CEO of Resyca, added, "Our patented nasal soft mist technology enables advanced drug delivery for both biologics and small molecules. Partnering with Cyrano Therapeutics aligns with our mission to drive innovation in drug delivery solutions. We believe this collaboration will help patients regain their sense of smell, achieve better treatment outcomes, and create a barrier to entry for any future competitors."

As the development of Cyrano Therapeutics' product CYR-064 progresses toward commercialization, Cyrano Therapeutics and Resyca are committed to bringing this innovative treatment to patients with chemosensory disorders. This partnership underscores their shared dedication to scientific innovation, patient-focused drug delivery, and advancing therapeutic solutions for smell loss.

Hyposmia, including post-viral hyposmia, is an increasingly prevalent and serious chronic sensory condition for which there is no approved drug therapy and limited treatment options. Hyposmia causes significant impairment in quality of life for many sufferers. Moreover, in older individuals, hyposmia is associated with an increased risk of cognitive impairment and mortality. There is currently no FDA-approved therapy indicated for the treatment of smell loss.

About Cyrano Therapeutics
Cyrano Therapeutics is a private, venture-backed clinical stage regenerative medicine company. Since our foundation, we have been working diligently to develop therapies for people struggling with the loss of smell and taste.

To learn more, please visit cyranotherapeutics.com.

About Resyca
Resyca® was founded in 2020 and is a joint venture between Bespak and Medspray. Resyca® specialises in the development and manufacturing of compact, user-friendly soft mist inhalation and soft nasal spray devices, incorporating the proprietary Medspray micro-nozzle technology. These devices are tailored for pulmonary and nasal applications, utilising standard pre-filled syringes / primary packaging and filling lines. As the soft mist development centre within Bespak, Resyca offers comprehensive services spanning from early-stage development through to commercial production, inclusive of filling, labelling, and packaging.
To learn more, please visit www.resyca.com

Media Contact:
Tiberend Strategic Advisors, Inc. 
Eric Reiss
[email protected] 

SOURCE Cyrano Therapeutics